How did Rigel Pharmaceuticals' revenue streams evolve in Q4 2024?

Rigel Pharmaceuticals' revenue streams in Q4 2024 were primarily driven by product sales and collaborations, with a total revenue of $144.9 million: 1. **Product Sales, Net**: The company generated $98.38 million from product sales, which is a significant portion of its total revenue. This indicates a strong performance in the market for its pharmaceutical products. 2. **Contract From Collaborations**: Rigel Pharmaceuticals also earned $34.38 million from contract revenues related to collaborations. This suggests that the company has been successful in leveraging partnerships to generate additional income streams. 3. **Contract From Collaborations**: The remaining $23.3 million came from contract revenues associated with collaborations. This contribution, while smaller than the net product sales, still represents a substantial amount of revenue and highlights the importance of partnerships in the company's business model. In summary, Rigel Pharmaceuticals' revenue streams in Q4 2024 were robust, with a strong focus on product sales and successful collaborations, which collectively contributed to the company's overall revenue. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |RIGL|RIGL.O|Rigel Pharmaceuticals|20240101-2024|Contract From Collaborations|3.4376E7|185| |RIGL|RIGL.O|Rigel Pharmaceuticals|20240101-2024|Contract From Collaborations|2.3302E7|185| |RIGL|RIGL.O|Rigel Pharmaceuticals|20240101-2024|Contract From Collaborations|6922000|185| |RIGL|RIGL.O|Rigel Pharmaceuticals|20240101-2024|Contract From Collaborations|3531000|185| |RIGL|RIGL.O|Rigel Pharmaceuticals|20240101-2024|Product Sales, Net|2.6003E7|185| |RIGL|RIGL.O|Rigel Pharmaceuticals|20240101-2024|Contract From Collaborations|3531000|185|